Roche and Itamar Medical Inc. Move Forward in Developing EndoPAT™ for Pre-Clinical Longitudinal Studies

CAESAREA, Israel--(BUSINESS WIRE)--Itamar-Medical (TASE: ITMR), the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials. This is a continuation of the original announcement from December 2010.

Back to news